Key points from article :
A new AI platform called Pi can detect prostate cancer in MRI scans.
Developed by Lucida Medical, a University of Cambridge spin-out company, Pi was backed by a cancer charity in the UK.
Macmillan Cancer Support has invested £350,100 in Lucida Medical's Pi as part of its Innovation Impact Investment Portfolio aimed at supporting innovative cancer care products.
Early detection of prostate cancer can improve survival rates and reduce unnecessary biopsies.
Pi's accuracy could save the healthcare system money and resources.
This technology has the potential to benefit both patients and the healthcare system.
Further development will involve people living with cancer to ensure patient-centered design.
